vimarsana.com

Latest Breaking News On - Eyepoint pharmaceuticals daily - Page 8 : vimarsana.com

EyePoint Pharmaceuticals (NASDAQ:EYPT) Trading Down 3 2%

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Get Free Report)’s share price fell 3.2% during mid-day trading on Friday . The stock traded as low as $21.85 and last traded at $22.12. 116,776 shares were traded during mid-day trading, a decline of 88% from the average session volume of 962,950 shares. The stock had previously closed at […]

EyePoint Pharmaceuticals (NASDAQ:EYPT) Price Target Lowered to $33 00 at HC Wainwright

EyePoint Pharmaceuticals (NASDAQ:EYPT – Free Report) had its target price reduced by HC Wainwright from $35.00 to $33.00 in a report released on Tuesday morning, Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for EyePoint Pharmaceuticals’ Q4 2023 earnings at ($0.40) EPS, FY2023 earnings at ($1.89) […]

Ye Liu Sells 1,910,500 Shares of EyePoint Pharmaceuticals, Inc (NASDAQ:EYPT) Stock

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Get Free Report) Director Ye Liu sold 1,910,500 shares of the business’s stock in a transaction on Thursday, January 11th. The shares were sold at an average price of $19.45, for a total value of $37,159,225.00. Following the completion of the sale, the director now owns 100,221 shares of the […]

EyePoint Pharmaceuticals, Inc (NASDAQ:EYPT) Major Shareholder Cormorant Asset Management, Lp Buys 105,000 Shares

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Get Free Report) major shareholder Cormorant Asset Management, Lp acquired 105,000 shares of the firm’s stock in a transaction dated Tuesday, January 9th. The stock was bought at an average price of $21.32 per share, with a total value of $2,238,600.00. Following the purchase, the insider now directly owns 6,143,235 […]

EyePoint Pharmaceuticals, Inc (NASDAQ:EYPT) Given Average Rating of Buy by Analysts

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Get Free Report) has been given an average rating of “Buy” by the six brokerages that are currently covering the firm, Marketbeat.com reports. Six equities research analysts have rated the stock with a buy rating. The average 1-year price objective among analysts that have issued a report on the stock […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.